Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 19Carcinoma, Hepatocellular 18Stomach Neoplasms 17Nasopharyngeal Carcinoma 15Triple Negative Breast Neoplasms 13Esophageal Squamous Cell Carcinoma 13Breast Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Esophageal Neoplasms 11Uterine Cervical Neoplasms 10Colorectal Neoplasms 10Sarcoma 9Melanoma 6Recurrence 5Neoplasm Metastasis 5Lung Neoplasms 5Hodgkin Disease 5Cholangiocarcinoma 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Osteosarcoma 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Liver Neoplasms 3Glioblastoma 3Gestational Trophoblastic Disease 3Endometrial Neoplasms 3Biliary Tract Neoplasms 3Solid Tumor 2Rectal Neoplasms 2NSCLC 2

Interventions

pembrolizumab 2Radiotherapy 2Etoposide 2Carboplatin 2sintilimab 1irinotecan sucrosofate 1durvalumab 1camrelizumab 1atezolizumab 1apatinib 1anlotinib 1amrubicin 1Platinum 1Paclitaxel 1NPI 2358 1Immunotherapy 1Immune Checkpoint Inhibitors 1Epirubicin 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Small Cell Lung Cancer Extensive Stage × camrelizumab × Clear all
NCT03755115 2019-01-16

SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer

Henan Cancer Hospital

Phase 2 Unknown
40 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡